KIT and neoplasm: Most patients had tumours harbouring mutations in KIT (n = 31, 62%), followed by PDGFR (n = 6, 12%) and the remaining had no mutations in KIT or PDGFRA (n = 4, 8%) (the characteristics of these patients are found in Table 2).